R&D

Jafron has solid research and development capabilities, with seven R&D centers and cooperative research institutions in Europe and China. It has collaborated with more than 80 international hospitals in clinical research and established several scientific research platforms such as the Guangdong Blood Purification Engineering Technology Research and Development Center, the Doctoral Research Workstation, the Postdoctoral Research Workstation, and the Academician Workstation. Meanwhile, Jafron has established a "Multi-Organ Support Therapy (MOST) Global Advisory Board," with six world-leading experts in the field of Blood purification and other 30 overseas experts.

Jafron continuously researched hemoperfusion products with many international hospitals and research centers, including two multi-center RCTs of HA130 in China and Observational Trial on Cytokine adsorption in Sepsis (OutCAST) in Germany, and several clinical studies of HA330/HA380 in Italy, Turkey, Spain, etc.

In addition, Jafron possesses 223 authorized patents, 22 medical product registration certificates, 114 product models.

R&D

Jafron has solid research and development capabilities, with seven R&D centers and cooperative research institutions in Europe and China. It has collaborated with more than 80 international hospitals in clinical research and established several scientific research platforms such as the Guangdong Blood Purification Engineering Technology Research and Development Center, the Doctoral Research Workstation, the Postdoctoral Research Workstation, and the Academician Workstation. Meanwhile, Jafron has established a "Multi-Organ Support Therapy (MOST) Global Advisory Board," with six world-leading experts in the field of Blood purification and other 30 overseas experts.

Jafron continuously researched hemoperfusion products with many international hospitals and research centers, including two multi-center RCTs of HA130 in China and Observational Trial on Cytokine adsorption in Sepsis (OutCAST) in Germany, and several clinical studies of HA330/HA380 in Italy, Turkey, Spain, etc.

In addition, Jafron possesses 223 authorized patents, 22 medical product registration certificates, 114 product models.

Innovation

The company owns products with ten series of more than 100 specifications, including Disposable Hemoperfusion Cartridge, Disposable Plasma Bilirubin Perfusion Adsorption Column, DNA Immunoadsorption Column, Hemoperfusion Machine and Blood Purification Machine, etc. Jafron provides new adsorption therapy, including "Combined Artificial Kidney," and "Double Plasma Molecular Adsorption System (DPMAS)," etc.

Jafron has mastered the core technology of Hemoperfusion, such as advanced coating technology which can improve blood compatibility to protect blood cells, nano-scale molecular sieve control technology which can accurately adjust the resin pore size distribution according to the toxin characteristics, etc.
The initial therapy developed by Jafron--"Direct Blood Adsorption," is widely used in uremia, liver failure, poisoning, lupus erythematosus and other critical illnesses.

Innovation

The company owns products with ten series of more than 100 specifications, including Disposable Hemoperfusion Cartridge, Disposable Plasma Bilirubin Perfusion Adsorption Column, DNA Immunoadsorption Column, Hemoperfusion Machine and Blood Purification Machine, etc. Jafron provides new adsorption therapy, including "Combined Artificial Kidney," and "Double Plasma Molecular Adsorption System (DPMAS)," etc.

Jafron has mastered the core technology of Hemoperfusion, such as advanced coating technology which can improve blood compatibility to protect blood cells, nano-scale molecular sieve control technology which can accurately adjust the resin pore size distribution according to the toxin characteristics, etc.
The initial therapy developed by Jafron--"Direct Blood Adsorption," is widely used in uremia, liver failure, poisoning, lupus erythematosus and other critical illnesses.

Quality Assurance

Jafron owned International Quality Certification such as CE, ISO, EN ISO13485, and China GMP National Certification. It possesses 56,000 square meters of production factories, including an international standard ISO-7 clean workshop, an ISO-5 clean operation room, and an automated production line of hemoperfusion cartridges.

The company benchmark against the highest medical standards and is equipped with a unique automated production line of hemoperfusion cartridges, which was initially developed by Jafron, with an annual capacity of about 20 million pieces. With the successful strategies and extremely rigorous evaluation methods on high production quality control, the yearly complaint rate of Jafron products is 0.1 per 10,000, which is much lower than the industry average.

Quality Assurance

Jafron owned International Quality Certification such as CE, ISO, EN ISO13485, and China GMP National Certification. It possesses 56,000 square meters of production factories, including an international standard ISO-7 clean workshop, an ISO-5 clean operation room, and an automated production line of hemoperfusion cartridges.

The company benchmark against the highest medical standards and is equipped with a unique automated production line of hemoperfusion cartridges, which was initially developed by Jafron, with an annual capacity of about 20 million pieces. With the successful strategies and extremely rigorous evaluation methods on high production quality control, the yearly complaint rate of Jafron products is 0.1 per 10,000, which is much lower than the industry average.

Application and Service

Twenty-five national medical guidelines or consensus of critical illness, liver disease, etc., recommend Jafron hemoadsorption therapy. And the therapy was also included in 11 national health care guidelines and recommendations for the treatment of Covid-19, including China, Morocco, the UK, Russia, Thailand, Iran, the Philippines, Columbia, Italy, India, Vietnam. With products, technologies and therapies available in 8,000 hospitals across more than 80 countries, the annual clinical application of Jafron reached 5 million cases.

Based in Asia, Jafron has established a global medical service network in blood purification, including 183 offices in China and five global service centers in Vietnam, Europe, South America, etc., with a professional therapy-providing team of over 1,100 staff and 1,000 partners.

Application and Service

Twenty-five national medical guidelines or consensus of critical illness, liver disease, etc., recommend Jafron hemoadsorption therapy. And the therapy was also included in 11 national health care guidelines and recommendations for the treatment of Covid-19, including China, Morocco, the UK, Russia, Thailand, Iran, the Philippines, Columbia, Italy, India, Vietnam. With products, technologies and therapies available in 8,000 hospitals across more than 80 countries, the annual clinical application of Jafron reached 5 million cases.

Based in Asia, Jafron has established a global medical service network in blood purification, including 183 offices in China and five global service centers in Vietnam, Europe, South America, etc., with a professional therapy-providing team of over 1,100 staff and 1,000 partners.

Talents

We are a team of more than 2800
employees and about 100 clinical medical
experts as senior advisors and special
advisors engaged in clinical trials and
teaching courses.

Talents


We are a team of more than 2800 employees and about 100 clinical medical experts as senior advisors and special advisors engaged in clinical trials and teaching courses.